Drug Interaction Potentiation, Inhibition Enzyme, Pharmacokinetics
Conditions
Brief summary
The purpose of the study is: * to determine absolute bioavailability, input rates, distribution volume, renal and intestinal excretion of trospium in subjects with wild-type of SLC22A1 rs72552763 and rs12208357 and in subjects with homozygous variant alleles of SLC22A1 rs72552763 or rs12208357 * to determine absolute bioavailability, input rates, distribution volume and renal and intestinal excretion of trospium in subjects with wild-type alleles of SLC22A1 rs72552763 and rs12208357 after co-medication of 300 mg of the OCT1- inhibitor ranitidine * to determine absolute bioavailability, input rates, distribution volume and renal and intestinal excretion of trospium in subjects with wild-type alleles of SLC22A1 rs72552763 and rs12208357 after co-medication of 500 mg of the P-glycoprotein- inhibitor clarithromycin * to determine absolute bioavailability, input rates, distribution volume and renal and intestinal excretion of trospium in subjects with homozygous variant alleles of SLC22A1 rs72552763 or rs12208357 after co-medication of 500 mg of the P-glycoprotein- inhibitor clarithromycin.
Interventions
DRUGintravenous infusion of 2 mg trospium chloride
intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o
DRUGoral administration of 30 mg trospium chloride
oral administration of 30 mg trospium chloride with 240 ml tap water
DRUGoral administration of 300 mg ranitidine
oral administration of 300 mg ranitidine with 240 ml tap water
DRUGoral administration of 500 mg clarithromycin
oral administration of 500 mg clarithromycin with 240 ml tap water
Sponsors
Dr. R. Pfleger Chemische Fabrik GmbH
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* ethnic origin: Caucasian * genotypes of OCT1: wild-type and homozygous variant alleles of SLC22A1 rs72552763 or rs12208357. * body mass index: ≥ 18.5 kg/m² and ≤ 30 kg/m² * good health as evidenced by the results of the clinical examination, ECG, and the laboratory check-up, which are judged by the clinical investigator not to differ in a clinical relevant way from the normal state (blood pressure between 110/70 and 140/90 for males and between 100/60 and 140/90 for females, heart rate over 50 bpm up to 90 bpm, laboratory values within the reference ranges as given actually by the laboratory and stored in the TMF) * written informed consent
Exclusion criteria
* hepatic and renal diseases and/or pathological findings, which might interfere with pharmacokinetics and pharmacodynamics of the study medication (e.g. hepatic or renal dysfunction, obstruction of the urine flow with urinary retention by subvesical obstruction like benign prostatic hyperplasia, infections or tumors of the urinary tract) * organic causes for polydipsia and pollakiuria * existing cardiac or hematological diseases and/or pathological findings, which might interfere with the drug's safety, tolerability and/or pharmacokinetics (e.g. tachycardia, tachyarrhythmia, bradycardia, heart failure, coronary heart disease, disturbance of the stimulus conduction) * pneumonia * pharyngitis * acute phorphyria * hyperthyroidism * galactose-intolerance, lactase deficiency or glucose-galactose malabsorption * electrolyte disturbance * gastrointestinal diseases and/or pathological findings (e.g. hiatus hernia with gastroesophageal reflux, stenosis, ulcera, severe chronic inflammatory bowel disease like ulcerative colitis or Crohn's disease, toxic megacolon), which might interfere with pharmacokinetics and pharmacodynamics of the study medication) * autonomic neuropathy * myasthenia gravis * narrow-angle glaucoma * drug or alcohol dependence * positive drug or alcohol screening * smokers of 10 or more cigarettes per day * positive results in HIV, HBV and HCV screenings * subjects who are on a diet which could affect the pharmacokinetics of the drugs (e. g. vegans, vegetarians) * heavy tea or coffee drinkers (more than 1L per day) * lactation, pregnancy test positive or not performed or women of child-bearing age without safe contraception as stated in the Note for Guidance on Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceutical (CPMP/ICH/286/95 modifications: implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomised partner and barrier-methods only in combination with one of the aforementioned) * subjects suspected or known not to follow instructions of the clinical investigators * subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study * subjects liable to orthostatic dysregulation, fainting, or blackouts * participation in a clinical trial during the last 3 months prior to the start of the study * less than 14 days after last acute disease * less than 3 months after last blood donation * any medication within 4 weeks prior to the intended first administration of the study medication which might influence functions of the gastrointestinal tract (e.g. laxatives, metoclopramide, loperamide, antacids, H2-receptor antagonists, proton pump inhibitors, anticholinergics) * any other medication within two weeks prior to the first administration of the study medication, but at least 10-time the half-live of the respective drug (except oral contraceptives) * intake of grapefruit or orange containing food or beverages within 14 days prior to administration of the study medication * intake of poppy seed containing food or beverages within 14 days prior to administration of the study medication * known allergic reactions to the active ingredients used, other H2-receptor antagonists, macrolide antibiotics or to constituents of the study medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| absolute bioavailability | up to 36 h after drug administration | ratio oral over intravenous area under the concentration time curve normalized by given dose |
Secondary
| Measure | Time frame |
|---|---|
| input rates | up to 36 h after drug administration |
| volume of distribution | up to 36 h after drug administration |
| renal excretion | up to 36 h after drug administration |
| intestinal excretion | up to 36 h after drug administration |
Outcome results
None listed